论文部分内容阅读
Dendritic cells (DCs) are potent antigen-presenting cells capable of inducing primary T-cell responses.Severalimmunotherapy treatment strategies involve manipulation of DCs,both in vivo and ex vivo,to promote theimmunogenic presentation of tumor-associated antigens.In this study,an electrofusion protocol was developedto induce fusion between osteosarcoma cells and aliogeneic bone marrow-derived DCs.Preimmunization withirradiated electrofusion products was found to provide partial or complete protection from tumor challenge inthe UMR106 tumor model.Vaccinated survivors developed long immunological memory.The therapeuticpotential of this type of approach was suggested by the ability of UMR106-DC electrofusion products whichcould induce tumor rejection in a substantial percentage (60%) of hosts hearing pre-established tumor cells.These results tended to indicate that treatment with electrofused tumor cells and allogeneic DCs might becapable of inducing a potent antitumor response and could conceivably be applied to a wide range of cancerindications for which tumor-associated antigens have not been identified.Cellular & Molecular Immunology.2004;1(6):454-460.
Dendritic cells (DCs) are potent antigen-presenting cells capable of inducing primary T-cell responses. Sevralimmunotherapy treatment strategies involve manipulation of DCs, both in vivo and ex vivo, to promote theimmunogenic presentation of tumor-associated antigens. In this study, an electrofusion protocol was developed to induce fusion between osteosarcoma cells and aliogeneic bone marrow-derived DCs. Preimmunization with irradiated electrofusion products was found to provide partial or complete protection from tumor challenge inthe UMR106 tumor model. Vaccinated survivors developed long immunological memory. The therapeutic potential of this type of approach was suggested by the ability of UMR106-DC electrofusion products which can induce tumor rejection in a substantial percentage (60%) of hosts hearing pre-established tumor cells. These results tended to indicate that treatment with electrofused tumor cells and allogeneic DCs might becapable of inducing a potent antitumor response and coul d conceivably be applied to a wide range of cancer applications for which tumor-associated antigens have not been identified. Cellular & Molecular Immunology. 2004; 1 (6): 454-460.